Cayuga Biotech
Biomimetic Solutions for Hemorrhage Control
Cayuga Biotech is a company in biopharma based in United States, founded in 2015.
Profile
Cayuga Biotech is a clinical-stage company developing novel therapeutics to address hemorrhage by harnessing the body’s innate ability to stop bleeding. Cayuga’s pipeline includes CAY001 (polyP-SNP complex) in development for life-threatening major hemorrhage; CAY002, a discovery-stage program for inherited bleeding disorders, and; a portfolio of additional early-stage programs across the healing continuum.
As a business in biopharma, Cayuga Biotech is listed here with the public details available about it.
Its base of operations is United States.
Directory data places it at the SOSV portfolio company stage.
Its team size is recorded as 2-10 employees.
Total disclosed funding stands at about $2.4M.
| Sector | Biopharma |
|---|---|
| Country | United States |
| Founded | 2015 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $2,400,000 |
Website: cayugabiotech.com
Create a free account